(Q43745098)

English

High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists

scientific article published in September 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

based on heuristic

inferred from title

author name string

Wang PR

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Guo Q

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Ippolito M

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Wu M

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Milot D

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Ventre J

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Doebber T

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Wright SD

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Chao YS

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

language of work or name

0 references

publication date

1 September 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

European Journal of Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

427

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

285-293

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Regulation of gallbladder cholesterol concentration in the hamster. Role of hepatic cholesterol level

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Review of European clinical experience with fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Demonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Role of muscle in triglyceride metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Triglyceride as a risk factor for coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Insulin resistance and lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Structure and biochemical effects of fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

The effects of different dietary fats and cholesterol on serum lipoprotein concentrations in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Fibrates, dyslipoproteinaemia and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901249-3

7 January 2021

Identifiers

10.1016/S0014-2999(01)01249-3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43745098&oldid=2102993444"